Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers

References

• Backes C, Ludwig N, Leidinger P, et al. (2011). Immunogenicity of autoantigens. BMC Genomics 12:340.
   PubMed Web of Science ®Google Scholar
• Calabrò L, Morra A, Fonsatti E, et al. (2013). Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14:1104–11.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Higano CS. (2011). PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17:3520–6.
   PubMed Web of Science ®Google Scholar
• Creaney J, Dick IM, Yeoman D, et al. (2011). Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma. PLoS One 6:e26515.
   PubMed Web of Science ®Google Scholar
• Creaney J, Ma S, Sneddon SA, et al. (2015). Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. Oncoimmunology 4:e1011492.
   PubMed Web of Science ®Google Scholar
• Creaney J, Olsen NJ, Brims F, et al. (2010). Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer. Epidemiol Biomarkers Prev 19:2238–46.
   PubMed Web of Science ®Google Scholar
• Finn OJ. (2008). Cancer immunology. N Engl J Med 358:2704–15.
   PubMed Web of Science ®Google Scholar
• Heemskerk B, Kvistborg P, Schumacher TN. (2013). The cancer antigenome. EMBO J 32:194–203.
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Friedman E, Verch T, et al. (2008). Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev 17:1520–6.
   PubMed Web of Science ®Google Scholar
• Ho M, Hassan R, Zhang J, et al. (2005). Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 11:3814–20.
   PubMed Web of Science ®Google Scholar
• Hollevoet K, Reitsma JB, Creaney J, et al. (2012). Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 30:1541–9.
   PubMed Web of Science ®Google Scholar
• Kyzas PA, Denaxa-Kyza D, Ioannidis JP. (2007). Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43:2559–79.
   PubMed Web of Science ®Google Scholar
• Leng SX, Mcelhaney JE, Walston JD, et al. (2008). ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci 63:879–84.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Salmons J, Nowak AK, et al. (2013). Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 8:e61895.
   PubMed Web of Science ®Google Scholar
• Marchand LS, St-Hilaire S, Putnam EA, et al. (2012). Mesothelial cell and anti-nuclear autoantibodies associated with pleural abnormalities in an asbestos exposed population of Libby MT. Toxicol Lett 208:168–73.
   PubMed Web of Science ®Google Scholar
• Pfau JC, Serve KM, Noonan CW. (2014). Autoimmunity and asbestos exposure. Autoimmune Dis 2014:782045.
   PubMedGoogle Scholar
• R Core Team. (2013). R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
   Google Scholar
• Robinson BW, Creaney J, Lake R, et al. (2003). Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612–16.
   PubMed Web of Science ®Google Scholar
• Robinson BW, Musk AW, Lake RA. (2005). Malignant mesothelioma. Lancet 366:397–408.
   PubMed Web of Science ®Google Scholar
• Robinson BWS, Lake RA. (2005). Advances in malignant mesothelioma. N Engl J Med 353:1591–603.
   PubMed Web of Science ®Google Scholar
• Robinson C, Callow M, Stevenson S, et al. (2000). Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J Respir Cell Mol Biol 22:550–6.
   PubMed Web of Science ®Google Scholar
• Robinson C, Robinson BWS, Lake RA. (1998). Sera from patients with malignant mesothelioma can contain autoantibodies. Lung Cancer 20:175–84.
   PubMed Web of Science ®Google Scholar
• Segal A, Sterrett GF, Frost FA, et al. (2013). A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 45:44–8.
   PubMed Web of Science ®Google Scholar
• Shukla A, Ramos-Nino M, Mossman B. (2003). Cell signaling and transcription factor activation by asbestos in lung injury and disease. Int J Biochem Cell Biol 35:1198–209.
   PubMed Web of Science ®Google Scholar
• Sims RB. (2012). Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 30:4394–7.
   PubMed Web of Science ®Google Scholar
• Threlfall T, Thompson J, Olsen N. (2005). Cancer in Western Australia: incidence and mortality 2003 and Mesothelioma 1960–2003. Department of Health, Perth, Western Australia. Statistical Series number 74.
   Google Scholar
• Walton SM, Gerlinger M, De La Rosa O, et al. (2006). Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immunol 177:8212–18.
   PubMed Web of Science ®Google Scholar
• Wayteck L, Breckpot K, Demeester J, et al. (2014). A personalized view on cancer immunotherapy. Cancer Lett 352:113–25.
   PubMed Web of Science ®Google Scholar
• Wong J, Sibani S, Lokko NN, et al. (2009). Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. J Immunol Methods 350:171–82.
   PubMed Web of Science ®Google Scholar
• Wuju L, Momiao X. (2002). Tclass: tumor classification system based on gene expression profile. Bioinformatics 18:325–6.
   PubMed Web of Science ®Google Scholar
• Zhang X, Shen W, Dong X, et al. (2013). Identification of novel autoantibodies for detection of malignant mesothelioma. PLoS One 8:e72458.
   PubMed Web of Science ®Google Scholar
• Zippelius A, Gati A, Bartnick T, et al. (2007). Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunol Immunother 56:249–58.
   PubMed Web of Science ®Google Scholar